The Fund Betting the Economy Will Soon Be Grown, Not Made
Jennifer Kan spent years at a Nobel laureate's bench teaching enzymes new tricks. Now her fund backs the founders trying to grow the physical economy - chocolate, copper, chemicals, even data - one engineered cell at a time.
There is a curve Jennifer Kan keeps coming back to. Over the last two decades, the cost of engineering DNA - reading it, writing it, teaching a cell to do something it was never born to do - has fallen by roughly 100,000 times. That is the kind of number that reshapes an industry before most people notice it happened. Kan's fund, Juniper, was built to notice.
Juniper is a San Diego venture firm that spun out of Climate Capital in December 2024. Its pitch is deceptively simple: for the first time, biology is cheap enough and precise enough to be treated as a manufacturing platform. Not a way to make drugs - Juniper stays out of pharma entirely - but a way to make the physical stuff of the economy. Chemicals. Materials. Food ingredients. Metals pulled from ore. Even data, stored in strands of DNA. The firm calls the shift the "bioindustrial revolution," and it writes the first institutional check into the companies trying to lead it.
That is a bold forecast, and Juniper knows it. But the firm's argument is less about faith than about arithmetic. If you can program a cell the way you program a chip, and the cost of doing so keeps collapsing, then whole categories of manufacturing become candidates for a biological rewrite - especially the ones that are hard to decarbonize any other way.
01 / The thesisBiology as a factory, not a pharmacy
Most people hear "synthetic biology" and think medicine. Juniper deliberately looks the other way. Its co-founder Michael Luciani, a former Washington policymaker and climate investor, frames the opportunity around the parts of the climate problem that get the least money. Energy and transportation attract the bulk of climate funding. Chemicals, plastics, cement, textiles, and food - the harder half - get comparatively little, even though they account for an enormous share of emissions.
Juniper's bet is that engineered biology is the best emerging tool for that neglected half. A microbe can be coached into producing a chemical that would otherwise come from petroleum. A plant cell can grow chocolate without a cacao farm. Proteins can pull copper out of low-grade ore. The common thread is not a single technology but a method: use living systems to make physical goods more cheaply, and often with a smaller carbon footprint, than the incumbent process.
02 / The checkWhat Juniper actually offers founders
Juniper invests early - pre-seed and seed - and aims to be the first institutional money in. Check sizes run roughly $100,000 to $500,000, and the firm can lead rounds. But the more interesting part of its model is not the size of the check. It is who is writing it.
Kan is not a generalist who read a few whitepapers on fermentation. She earned a PhD at the University of Cambridge and did enzyme-engineering work at Caltech in the lab of Frances Arnold, who won the 2018 Nobel Prize in Chemistry for directed evolution. Kan's work was highlighted in Arnold's Nobel lecture. When a scientist-founder walks into a pitch, they are being evaluated by someone who has stood at the same bench.
That technical fluency shows up in diligence. Kan has spoken publicly about the mistakes scientist-founders make most often - chief among them, skipping the techno-economic analysis that tells you whether a beautiful lab result can ever be cheap enough to sell. Juniper's support model leans into exactly those gaps: intellectual-property strategy, supply-chain partnerships, and help crossing what the industry calls the "valley of death" between a working prototype and a shipping product.
03 / The portfolioFrom de-extinction to DNA hard drives
Juniper's roughly 27 companies read, at first glance, like a science-fiction anthology. And then the logic clicks into place. Each one is an attempt to make a physical thing using biology instead of the incumbent industrial process.
A sample of the portfolio. Others span oxygen-free fermentation, engineered photosynthesis, biological copper extraction, and AI infrastructure for living systems.
04 / The contrarian moveBuying while others sell
Timing is where Juniper gets genuinely interesting. The last biology-for-industry boom, alternative proteins, has cratered. By Kan's own accounting, investment in the category fell 56% - from about $1.5 billion in 2023 to roughly $66 million across the first three quarters of 2025. For most investors, that is a flashing sign to stay away.
Juniper reads it differently. Kan has argued that the earlier bubble collapsed because too many companies skipped the hard economics and over-promised on timelines - not because the underlying science stopped working. A cheaper capital environment, a wiser set of founders, and better AI and robotics tools to reach revenue faster make the down cycle, in her view, a buying window rather than a warning.
05 / The businessHow Juniper makes money, and how it competes
Underneath the science, Juniper is a conventional venture fund. It raises capital from limited partners - family offices, foundations, individual field scientists who came in at reduced minimums, and an institutional anchor in the fund-of-funds Allocator One - and deploys it as equity into early-stage startups. It earns management fees and carried interest when those bets pay off. The GPs point to a pre-Juniper track record across 40-plus deep-tech investments to make the case.
The competition is other technical, climate-leaning deep-tech funds. Where Juniper tries to win is on two axes at once: a deliberate focus on industrial biology rather than healthcare, and a level of scientific credibility that lets a small check punch above its weight. When your general partner was cited in a Nobel lecture, you can sometimes win a founder against a term sheet three times your size.
06 / The timeline
None of this guarantees the 2040 forecast comes true. Grown-not-made is still a minority position, and the graveyard of over-hyped biotech is real. But Juniper's wager is coherent: back the industrial side of biology, back it early, and bring enough technical judgment to tell the durable companies from the beautiful demos. If the DNA-cost curve keeps bending the way it has, the firm will not have to convince anyone. The factories will.
FAQQuestions people ask about Juniper
What does Juniper invest in?
Early-stage companies using biology, engineering, and computation for industrial applications - biomanufacturing, chemicals, materials, food, mining, and biocomputing. It deliberately avoids pharma and healthcare.
Who founded Juniper?
Jennifer (Jenny) Kan, a Cambridge-trained enzyme engineer and General Partner, co-founded it with Michael Luciani, a climate investor and founding partner. It spun out of Climate Capital in December 2024.
How big is the fund and what checks does it write?
Fund I is an oversubscribed fund of roughly $10.6M, writing first checks of about $100K-$500K at pre-seed and seed, with the ability to lead rounds.
How is Juniper different from other VC firms?
Its partners come from the bench and from climate policy, so it offers technical diligence and hands-on support - IP strategy, supply chains, techno-economic analysis - and focuses on industrial biology rather than drugs.
Where is Juniper based?
Juniper is headquartered in San Diego, California, with team members across the San Francisco Bay Area.